Atholl Johnston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/376607/publications.pdf

Version: 2024-02-01

245 papers

7,708 citations

50276 46 h-index 69250 77 g-index

246 all docs

246 docs citations

246 times ranked 6289 citing authors

#	Article	IF	Citations
1	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. Therapeutic Drug Monitoring, 2009, 31, 139-152.	2.0	398
2	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation, 2002, 74, 1486-1489.	1.0	283
3	Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clinical Therapeutics, 2002, 24, 330-350.	2.5	264
4	The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation. American Journal of Transplantation, 2004, 4, 914-919.	4.7	238
5	Evidence for a Difference in Nitric Oxide Biosynthesis Between Healthy Women and Men. Hypertension, 1998, 32, 730-734.	2.7	196
6	Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. Transplantation, 2005, 79, 499-502.	1.0	178
7	Influence of Donor C3 Allotype on Late Renal-Transplantation Outcome. New England Journal of Medicine, 2006, 354, 2014-2023.	27.0	176
8	Substandard drugs: a potential crisis for public health. British Journal of Clinical Pharmacology, 2014, 78, 218-243.	2.4	174
9	Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney International, 2007, 72, 1429-1447.	5.2	166
10	Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia, 2001, 44, 706-712.	6.3	133
11	Consensus Document: Hawk's Cay Meeting on Therapeutic Drug Monitoring of Cyclosporine. Clinical Chemistry, 1990, 36, 1510-1516.	3.2	132
12	STRIPE: An interactive computer program for the analysis of drug pharmacokinetics. Journal of Pharmacological Methods, 1983, 9, 193-199.	0.7	118
13	Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current Algorithms. Therapeutic Drug Monitoring, 2001, 23, 100-114.	2.0	114
14	Variable Bioavailability of Oral Melatonin. New England Journal of Medicine, 1997, 336, 1028-1029.	27.0	111
15	Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Alterations in Cortisol Pharmacokinetics at Puberty. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2701-2708.	3.6	108
16	Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. European Journal of Clinical Pharmacology, 2012, 68, 853-856.	1.9	106
17	Impact of Absorption Profiling on Efficacy and Safety of Cyclosporin Therapy in Transplant Recipients. Clinical Pharmacokinetics, 2000, 39, 117-125.	3.5	100
18	Acute effects of singleâ€dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Human Brain Mapping, 2013, 34, 272-282.	3.6	97

#	Article	IF	Citations
19	Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Endocrinology, 2001, 169, 65-70.	2.6	92
20	Neoral absorption profiling: an evolution in effectiveness. Transplantation Proceedings, 2000, 32, S45-S52.	0.6	86
21	Validation of an Assay for Routine Monitoring of Sirolimus Using HPLC with Mass Spectrometric Detection. Clinical Chemistry, 2000, 46, 1179-1183.	3.2	83
22	Serum Cortisol and 17-Hydroxyprogesterone Interrelation in Classic 21-Hydroxylase Deficiency: Is Current Replacement Therapy Satisfactory?. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4679-4685.	3.6	76
23	Recommendations for the Implementation of Neoral C2 Monitoring in Clinical Practice. Transplantation, 2002, 73, S19-S22.	1.0	76
24	Augmentation of venous, arterial and microvascular blood supply in the leg by isometric neuromuscular stimulation via the peroneal nerve. International Journal of Angiology, 2010, 19, e31-e37.	0.6	74
25	Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. Journal of Chromatography A, 1981, 218, 621-629.	3.7	72
26	Methodological and Clinical Aspects of Cyclosporin Monitoring: Report of the Association of Clinical Biochemists Task Force. Annals of Clinical Biochemistry, 1994, 31, 420-446.	1.6	72
27	Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the international neoral \hat{A}^{\otimes} tdm advisory consensus meeting (vancouver, november 1997). Transplantation Proceedings, 1998, 30, 1645-1649.	0.6	72
28	Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1611-1616.	3.6	67
29	A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clinical Therapeutics, 2003, 25, 1654-1669.	2.5	67
30	Therapeutic drug monitoring of immunosuppressant drugs. British Journal of Clinical Pharmacology, 1999, 47, 339-350.	2.4	65
31	Variable bioavailability following repeated oral doses of etoposide. European Journal of Cancer & Clinical Oncology, 1985, 21, 1315-1319.	0.7	59
32	Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes, 2000, 49, 857-862.	0.6	59
33	Use of Neoral C2 monitoring: a European consensus. Transplant International, 2005, 18, 768-778.	1.6	59
34	Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney International, 2000, 57, 1164-1168.	5.2	58
35	Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra < sup > \hat{A}^{\otimes} < /sup >) in treatment of patients with trigeminal neuralgia. European Journal of Neurology, 2009, 16, 740-744.	3.3	55
36	The Need for Standardization of Tacrolimus Assays. Clinical Chemistry, 2011, 57, 1739-1747.	3.2	55

#	Article	IF	CITATIONS
37	The influence of cimetidine on the pharmacokinetics of 5â€fluorouracil British Journal of Clinical Pharmacology, 1984, 18, 421-430.	2.4	52
38	Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clinical Therapeutics, 2000, 22, B38-B48.	2.5	52
39	An immunoassay for the measurement of sirolimus. Clinical Therapeutics, 2000, 22, B49-B61.	2.5	52
40	A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. Journal of Neural Transmission, 2003, 110, 1257-1271.	2.8	52
41	New Approaches to Cyclosporine Monitoring Raise Further Concerns about Analytical Techniques. Clinical Chemistry, 2000, 46, 872-874.	3.2	51
42	Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral®) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatric Transplantation, 2003, 7, 282-288.	1.0	50
43	Bioequivalence of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: A Meta-Analysis of Three Studies in Stable Renal Transplant Recipients. Transplantation, 2006, 82, 1413-1418.	1.0	50
44	Monitoring Cyclosporin in Blood: Between-Assay Differences at Trough and 2 Hours Post-dose (C2). Therapeutic Drug Monitoring, 2003, 25, 167-173.	2.0	48
45	Effectiveness, safety and cost of drug substitution in hypertension. British Journal of Clinical Pharmacology, 2010, 70, 320-334.	2.4	47
46	Simple Bioequivalence Criteria. Therapeutic Drug Monitoring, 1997, 19, 375-381.	2.0	47
47	Systemic availability of oral verapamil and effect on PR interval in man British Journal of Clinical Pharmacology, 1981, 12, 397-400.	2.4	46
48	RELATIVE BIOAVAILABILITY OF CONTROLLED RELEASE MORPHINE TABLETS (MST CONTINUS) IN CANCER PATIENTS. British Journal of Anaesthesia, 1988, 61, 569-574.	3.4	46
49	Accuracy of Cyclosporin Measurements Made in Capillary Blood Samples Obtained by Skin Puncture. Therapeutic Drug Monitoring, 2000, 22, 594-598.	2.0	44
50	Effective Synthesis of 1β-Acyl Glucuronides by Selective Acylation. Organic Letters, 2005, 7, 2591-2594.	4.6	43
51	A survey to determine the views of renal transplant patients on generic substitution in the UK. Transplant International, 2011, 24, 770-779.	1.6	43
52	Development and Evaluation of a Composite Risk Score to Predict Kidney Transplant Failure. American Journal of Kidney Diseases, 2011, 57, 744-751.	1.9	43
53	The effect of dose on the bioavailability of oral etoposide. Cancer Chemotherapy and Pharmacology, 1986, 16, 178-81.	2.3	42
54	Comparison of the Predictive Performance of eGFR Formulae for Mortality and Graft Failure in Renal Transplant Recipients. Transplantation, 2009, 87, 384-392.	1.0	40

#	Article	IF	CITATIONS
55	Multicenter, randomized controlled, observerâ€blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetesâ€"ProNOx1 study. Wound Repair and Regeneration, 2018, 26, 228-237.	3.0	40
56	Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. British Journal of Clinical Pharmacology, 2011, 72, 727-730.	2.4	39
57	Visual assessment of the timing of bruising by forensic experts. Journal of Clinical Forensic and Legal Medicine, 2010, 17, 143-149.	1.0	38
58	Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. European Journal of Hospital Pharmacy, 2013, 20, 302-307.	1.1	38
59	The digoxin-amiodarone interaction. Cardiovascular Drugs and Therapy, 1989, 3, 25-28.	2.6	37
60	Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. Vascular Pharmacology, 2015, 71, 70-78.	2.1	37
61	Mexiletine in human blood and breast milk Postgraduate Medical Journal, 1981, 57, 546-547.	1.8	36
62	Immunosuppressant drugs – the role of therapeutic drug monitoring. British Journal of Clinical Pharmacology, 2001, 52, 61-73.	2.4	36
63	Pharmacokinetic interaction between theophylline and erythromycin British Journal of Clinical Pharmacology, 1982, 14, 495-499.	2.4	34
64	simp: A computer program in basic for nonlinear curve fitting. Journal of Pharmacological Methods, 1985, 14, 323-329.	0.7	34
65	Measurement of S-nitrosothiols in extracellular fluids from healthy human volunteers and rheumatoid arthritis patients, using electron paramagnetic resonance spectrometry. Free Radical Biology and Medicine, 2005, 39, 937-948.	2.9	34
66	The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. British Journal of Cancer, 1985, 52, 363-367.	6.4	33
67	High-performance liquid chromatography of etoposide in plasma and urine. Biomedical Applications, 1985, 339, 419-423.	1.7	32
68	Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment British Journal of Clinical Pharmacology, 1980, 10, 245-248.	2.4	31
69	The United Kingdom Cyclosporin Quality Assessment Scheme. Therapeutic Drug Monitoring, 1986, 8, 200-204.	2.0	31
70	A new method to monitor drugs at dance venues. BMJ: British Medical Journal, 2001, 323, 603-603.	2.3	31
71	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by CO or C2 measurements. Clinical Transplantation, 2007, 21, 252-257.	1.6	31
72	The influence of urinary pH on flecainide excretion and its serum pharmacokinetics British Journal of Clinical Pharmacology, 1984, 17, 447-451.	2.4	30

#	Article	IF	CITATIONS
73	The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing. Results in Pharma Sciences, 2012, 2, 1-8.	4.2	30
74	Analysis for Identification in Amnesty Bin Samples from Dance Venues. Therapeutic Drug Monitoring, 2005, 27, 793-798.	2.0	29
75	Cyclosporin A: Analytical Methodology and Factors Affecting Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 1995, 17, 625-630.	2.0	28
76	Single oral doses of netazepide (<scp>YF</scp> 476), a gastrin receptor antagonist, cause doseâ€dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Alimentary Pharmacology and Therapeutics, 2012, 36, 181-189.	3.7	28
77	Chlortenoxicam pharmacokinetics in young and elderly human volunteers Postgraduate Medical Journal, 1988, 64, 752-754.	1.8	27
78	Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage British Journal of Clinical Pharmacology, 1989, 28, 463-469.	2.4	27
79	Lack of effect of interferon $\hat{l}\pm 2a$ upon fluorouracil pharmacokinetics. British Journal of Cancer, 1994, 70, 724-728.	6.4	27
80	The Impact of Hemoglobin Levels on Patient and Graft Survival in Renal Transplant Recipients. Transplantation, 2008, 86, 564-570.	1.0	27
81	†Ivory wave' toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning. Clinical Toxicology, 2012, 50, 108-113.	1.9	27
82	The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers British Journal of Clinical Pharmacology, 1979, 8, 349-352.	2.4	26
83	Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH British Journal of Clinical Pharmacology, 1985, 20, 333-338.	2.4	25
84	The effect of vehicle on the oral absorption of cyclosporin British Journal of Clinical Pharmacology, 1986, 21, 331-333.	2.4	25
85	Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. European Journal of Clinical Pharmacology, 1993, 44, 63-67.	1.9	25
86	Pharmacokinetics of Cyclosporine and Multipleâ€Dose Diclofenac During Coadministration. Journal of Clinical Pharmacology, 1993, 33, 936-943.	2.0	25
87	Pharmacokinetics of a new testosterone transdermal delivery system, TDSR-testosterone in healthy males. British Journal of Clinical Pharmacology, 2006, 61, 275-279.	2.4	25
88	The efficiency of protective gloves used in the handling of cytotoxic drugs. Cancer Chemotherapy and Pharmacology, 1984, 12, 151-3.	2.3	24
89	Effect of grapefruit juice on blood cyclosporin concentration. Lancet, The, 1995, 346, 122-124.	13.7	24
90	Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation. Liver Transplantation, 2002, 8, 224-232.	2.4	24

#	Article	IF	Citations
91	Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. European Journal of Clinical Pharmacology, 2004, 60, 389-95.	1.9	24
92	Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Current Medical Research and Opinion, 2010, 26, 871-878.	1.9	24
93	Quality Assessment Issues of New Immunosuppressive Drugs and Experimental Experience. Therapeutic Drug Monitoring, 1996, 18, 362-367.	2.0	24
94	Concentration-Controlled Trials. Clinical Pharmacokinetics, 1995, 28, 93-99.	3.5	23
95	Renal Transplantation in Indo-Asian Patients in the UK. American Journal of Transplantation, 2006, 6, 761-769.	4.7	23
96	Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 $\hat{a}\in$ A potential risk to users?. Drug Testing and Analysis, 2019, 11, 1172-1182.	2.6	23
97	The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia British Journal of Clinical Pharmacology, 1981, 12, 507-510.	2.4	22
98	Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Alterations in Cortisol Pharmacokinetics at Puberty. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2701-2708.	3.6	22
99	Proficiency-testing issues relating to sirolimus. Clinical Therapeutics, 2000, 22, B122-B132.	2.5	21
100	Oral Hydrocortisone Administration in Children with Classic 21-Hydroxylase Deficiency Leads to More Synchronous Joint GH and Cortisol Secretion. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2238-2244.	3.6	21
101	The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplantation Proceedings, 2004, 36, 3223-3225.	0.6	21
102	A microparticle enzyme immunoassay to measure sirolimus. Transplantation Proceedings, 2005, 37, 182-184.	0.6	21
103	Intravenous Parecoxib Rapidly Leads to COX-2 Inhibitory Concentration of Valdecoxib in the Central Nervous System. Clinical Pharmacology and Therapeutics, 2008, 83, 430-435.	4.7	21
104	Cyclosporin Microemulsion. BioDrugs, 1997, 7, 175-197.	4.6	20
105	A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. European Journal of Clinical Pharmacology, 2012, 68, 349-353.	1.9	20
106	Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	20
107	The acute changes in serum binding of disopyramide and flecainide after myocardial infarction. European Journal of Clinical Pharmacology, 1985, 28, 253-255.	1.9	19
108	Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgraduate Medical Journal, 1988, 64, 361-363.	1.8	19

#	Article	IF	CITATIONS
109	Effect of Terbinafine on the Pharmacokinetics of Cyclosporin in Humans. Journal of Investigative Dermatology, 1994, 102, 740-743.	0.7	19
110	Genotyping cytochrome P450 3A5 using the Light Cycler. Annals of Clinical Biochemistry, 2005, 42, 376-381.	1.6	19
111	The relationship between theophylline clearance and age in adult life. European Journal of Clinical Pharmacology, 1989, 36, 29-34.	1.9	18
112	Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgraduate Medical Journal, 1994, 70, 363-366.	1.8	18
113	Monitoring New Immunosuppressive Agents Are the Methods Adequate?. Drug Metabolism and Drug Interactions, 1997, 14, 5-16.	0.3	18
114	Plasma Clozapine and Norclozapine in Patients Prescribed Different Brands of Clozapine (Clozaril,) Tj ETQq0 0 0	rgBT/Ove	erlock 10 Tf 50
115	First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam. European Journal of Clinical Pharmacology, 2013, 69, 361-363.	1.9	18
116	Cocoa flavanols reduce Nâ€terminal proâ€Bâ€type natriuretic peptide in patients with chronic heart failure. ESC Heart Failure, 2016, 3, 97-106.	3.1	18
117	The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers British Journal of Clinical Pharmacology, 1986, 21, 389-392.	2.4	17
118	Bioequivalence criteria for cyclosporine. Transplantation Proceedings, 1999, 31, 1649-1653.	0.6	17
119	Cannabis use: a perspective in relation to the proposed UK drugâ€driving legislation. Drug Testing and Analysis, 2014, 6, 143-154.	2.6	17
120	Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. Bioanalysis, 2018, 10, 1229-1248.	1.5	17
121	Serum Cortisol and 17-Hydroxyprogesterone Interrelation in Classic 21-Hydroxylase Deficiency: Is Current Replacement Therapy Satisfactory?. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4679-4685.	3.6	17
122	A Study of the Interaction between Lornoxicam and Warfarin in Healthy Volunteers. Human and Experimental Toxicology, 1990, 9, 413-414.	2.2	16
123	Noeral C-2 monitoring in cardiac transplant patients. Transplantation Proceedings, 2001, 33, 1572-1575.	0.6	16
124	Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Transplant International, 2002, 15, 649-654.	1.6	16
125	Pharmacokinetics of Orally Administered Cyclosporine in Patients with Crohn's Disease. Journal of Clinical Pharmacology, 1995, 35, 681-687.	2.0	15
126	Plasma Nitrate Concentrations in Children with Infectious and Noninfectious Diarrhea. Journal of Pediatric Gastroenterology and Nutrition, 2001, 32, 423-427.	1.8	15

#	Article	IF	CITATIONS
127	The effects and metabolic fate of nitroflurbiprofen in healthy volunteers. Clinical Pharmacology and Therapeutics, 2004, 76, 350-358.	4.7	14
128	Novel therapies in transplantation. Expert Opinion on Investigational Drugs, 2005, 14, 295-304.	4.1	14
129	Validation of High-Performance Liquid ChromatographicMass Spectrometric Method for the Analysis of Lidocaine in Human Plasma. Journal of Chromatographic Science, 2006, 44, 262-265.	1.4	14
130	Trends in less-lethal use of force techniques by police services within England and Wales: 2007–2011. Forensic Science, Medicine, and Pathology, 2014, 10, 50-55.	1.4	14
131	The effectiveness of a novel neuromuscular electrostimulation method versus intermittent pneumatic compression in enhancing lower limb blood flow. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2014, 2, 160-165.	1.6	14
132	Gas—liquid chromatographic method for the routine estimation of disopyramide in plasma or serum. Journal of Chromatography A, 1978, 152, 501-506.	3.7	13
133	A single-dose comparison of four slow-release theophylline preparations in normal subjects. Postgraduate Medical Journal, 1981, 57, 153-155.	1.8	13
134	The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers British Journal of Clinical Pharmacology, 1986, 21, 385-388.	2.4	13
135	Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men Postgraduate Medical Journal, 1990, 66, 622-626.	1.8	13
136	Cyclosporin monitoring: Its role in autoimmune indications. Journal of Autoimmunity, 1992, 5, 177-182.	6.5	13
137	Validation of self-reported khat chewing amongst khat chewers: An exploratory study. Journal of Ethnopharmacology, 2012, 140, 193-196.	4.1	13
138	Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. Journal of Feline Medicine and Surgery, 2018, 20, 704-710.	1.6	13
139	β-Lactam antimicrobial Âpharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3625-3634.	3.0	13
140	Subcutaneous infusion of cytosine arabinoside. Cancer Chemotherapy and Pharmacology, 1983, 10, 112-114.	2.3	12
141	The bioavailability of oral intermediate-dose methotrexate. Cancer Chemotherapy and Pharmacology, 1984, 13, 91-4.	2.3	12
142	Generic substitution for cyclosporine: what should we be looking for in new formulations?. Transplantation Proceedings, 1998, 30, 1652-1653.	0.6	12
143	Is circadian variation in theophylline trough serum concentrations determined by time of dosing?. British Journal of Clinical Pharmacology, 1984, 17, 777-779.	2.4	11
144	The influence of haematocrit on blood cyclosporin measurements in vivo British Journal of Clinical Pharmacology, 1988, 25, 509-513.	2.4	11

#	Article	IF	Citations
145	Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?. Transplantation Proceedings, 2004, 36, 1321-1326.	0.6	11
146	Seeking Optimal Prescription of Cyclosporine ME. Therapeutic Drug Monitoring, 2005, 27, 3-6.	2.0	11
147	Generic and therapeutic substitutions: are they always ethical in their own terms?. International Journal of Clinical Pharmacy, 2010, 32, 691-695.	1.4	11
148	A herbal treatment for type 2 diabetes adulterated with undisclosed drugs. Lancet, The, 2018, 391, 2411.	13.7	11
149	The measurement of lignocaine at low concentrations in plasma, a comparison of gas liquid chromatography with enzyme immunoassay British Journal of Clinical Pharmacology, 1979, 8, 598-599.	2.4	10
150	A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension British Journal of Clinical Pharmacology, 1988, 26, 53-59.	2.4	10
151	Monitoring cyclosporin: is it still important?. Immunology Letters, 1991, 29, 99-103.	2.5	10
152	Cyclosporin Measurement – who cares about inaccuracy?. Accreditation and Quality Assurance, 2001, 6, 405-408.	0.8	10
153	CYP3A5 Genotype Does Not Influence the Blood Concentration of Tacrolimus Measured with the Abbott Immunoassay. Clinical Chemistry, 2005, 51, 2214-2215.	3.2	10
154	Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Transplant International, 2002, 15, 649-654.	1.6	10
155	Saliva theophylline concentrations after a single oral dose British Journal of Clinical Pharmacology, 1982, 13, 243-245.	2.4	9
156	CONCENTRATION OF D-PROPRANOLOL IN CERVICOVAGINAL MUCUS. Lancet, The, 1984, 324, 1480.	13.7	9
157	A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam Postgraduate Medical Journal, 1993, 69, 865-866.	1.8	9
158	Quality Assurance Programs for Immunosuppressive Drugs. Therapeutic Drug Monitoring, 1993, 15, 472-477.	2.0	9
159	Effects of single and repeated oral doses of TAK-013, a new non-peptide gonadotropin-releasing hormone (GnRH) antagonist, in healthy post-menopausal women. Fertility and Sterility, 2002, 78, S281-S282.	1.0	9
160	Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplantation Proceedings, 2004, 36, 2993-2996.	0.6	9
161	Validation and application of capillary electrophoresis for the analysis of lidocaine in a skin tape stripping study. Biomedical Chromatography, 2007, 21, 775-779.	1.7	9
162	Total body water is the preferred method to use in forensic blood-alcohol calculations rather than ethanol's volume of distribution. Forensic Science International, 2020, 316, 110532.	2.2	9

#	Article	IF	Citations
163	The pharmacokinetics of lysine theophylline, a new soluble theophylline, in human volunteers Postgraduate Medical Journal, 1983, 59, 86-87.	1.8	8
164	Delayed-release bleomycin. Cancer Chemotherapy and Pharmacology, 1984, 13, 19-21.	2.3	8
165	Circadian variation in theophylline absorption during chronic dosing with a slow release theophylline preparation and the effect of clock time of dosing British Journal of Clinical Pharmacology, 1988, 26, 73-77.	2.4	8
166	Aspartame Pharmacokinetics—The Effect of Ageing. Age and Ageing, 1996, 25, 217-220.	1.6	8
167	Death rate from use of ecstasy or heroin. Lancet, The, 1999, 354, 2166.	13.7	8
168	Comparative Pharmacokinetic Assessments of Topical Drugs: Evaluation by Dermatopharmacokinetics, Microdialysis, and Systemic Measurement. Journal of Investigative Dermatology, 2010, 130, 2828-2830.	0.7	8
169	Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extendedâ€release tacrolimus preparation. Clinical and Translational Science, 2022, 15, 70-78.	3.1	8
170	The relationship between clearance of theophylline and age within the adult age range. European Journal of Clinical Pharmacology, 1985, 29, 177-179.	1.9	7
171	Amenamevir: Studies of Potential CYP3Aâ€Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2018, 7, 844-859.	1.6	7
172	Rapid Quantitation of Flecainide in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography and Time-of-Flight Mass Spectrometry. Therapeutic Drug Monitoring, 2019, 41, 391-395.	2.0	7
173	The analysis of doseâ€response curvesâ€a practical approach British Journal of Clinical Pharmacology, 1987, 23, 199-205.	2.4	6
174	A psychopharmacological study to assess anti-muscarinic and central nervous effects of medifoxamine in normal volunteers. Human Psychopharmacology, 1988, 3, 195-200.	1.5	6
175	Pharmacokinetic Interaction Between Indoramin and Ethanol. Human Toxicology, 1989, 8, 237-241.	0.9	6
176	Cyclosporin assay techniques. Accuracy and reproducibility variables impacting on measurements. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 733-736.	0.3	6
177	The Effect of Repeated Oral Doses of Lornoxicam on Antipyrine Elimination in Normal Human Volunteers. Human and Experimental Toxicology, 1991, 10, 375-377.	2.2	6
178	Pharmacokinetics of Cyclosporine and Steadyâ€State Aspirin During Coadministration. Journal of Clinical Pharmacology, 1993, 33, 513-521.	2.0	6
179	A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients. Transplantation Proceedings, 2004, 36, 3239-3241.	0.6	6
180	Monitoring Immunosuppressive Drugs. Therapeutic Drug Monitoring, 2004, 26, 244-247.	2.0	6

#	Article	IF	Citations
181	Risk Factors for Allograft Failure in United Kingdom Renal Transplant Recipients Treated with Cyclosporine A. Transplantation, 2005, 79, 953-957.	1.0	6
182	Convenient syntheses of the in vivo carbohydrate metabolites of mycophenolic acid: reactivity of the acyl glucuronide. Tetrahedron Letters, 2009, 50, 4973-4977.	1.4	6
183	Development of HPLCâ€UV method for rapid and sensitive analysis of topically applied tetracaine: its comparison with a CZE method. Biomedical Chromatography, 2014, 28, 826-830.	1.7	6
184	Using tramadol to measure CYP2D6 metabolism in critically ill adults. Intensive Care Medicine, 2014, 40, 1177-1178.	8.2	6
185	Amenamevir: Studies of Potential CYP2C8―and CYP2B6â€Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2018, 7, 860-870.	1.6	6
186	Simultaneous quantification of cyclosporin, tacrolimus, sirolimus and everolimus in whole blood by UHPLC–MS/MS for therapeutic drug monitoring. Biomedical Chromatography, 2021, 35, e5071.	1.7	6
187	Concentration ofd-propranolol in cervico-vaginal mucus: targeting of a novel spermicide. Advances in Contraception: the Official Journal of the Society for the Advancement of Contraception, 1985, 1, 103-108.	0.3	5
188	A Study of the Interaction between Oxytetracycline and Pyridostigmine. Human Toxicology, 1988, 7, 263-266.	0.9	5
189	Medifoxamine: Oral tolerance and pharmacokinetic study in healthy human volunteers. European Journal of Clinical Pharmacology, 1990, 39, 169-171.	1.9	5
190	An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine. European Journal of Clinical Pharmacology, 1990, 39, 405-407.	1.9	5
191	Automatic on-line extraction coupled with electrochemical detection as an improved method for the HPLC co-analysis of codeine and morphine in plasma and gastric juice. Journal of Pharmaceutical and Biomedical Analysis, 1990, 8, 1021-1027.	2.8	5
192	Cyclosporin and vitamin E. Lancet, The, 1991, 338, 697.	13.7	5
193	Immunosuppressant drugs – the role of therapeutic drug monitoring. British Journal of Clinical Pharmacology, 2001, 52, 61-73.	2.4	5
194	Patient management by cyclosporine C2 monitoring. Transplantation, 2004, 77, 323-324.	1.0	5
195	Circulation Time in Man from Lung to Periphery as an Indirect Index of Cardiac Output. , 2005, 566, 311-316.		5
196	The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: A prospective cohort study. Journal of Dermatological Treatment, 2011, 22, 79-85.	2.2	5
197	The systemic availability of a slow release rectal preparation of lignocaine [proceedings]. British Journal of Clinical Pharmacology, 1978, 6, 442P-443P.	2.4	4
198	The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension. Investigational New Drugs, 1984, 2, 271-6.	2.6	4

#	Article	IF	Citations
199	Stability of plasma amiodarone levels during chronic oral therapy. Cardiovascular Drugs and Therapy, 1990, 4, 529-530.	2.6	4
200	Plasma metronidazole concentrations after single and repeated vaginal pessary administration British Journal of Clinical Pharmacology, 1991, 32, 621-623.	2.4	4
201	Influence of lornoxicam a new non-steroidal antiinflammatory drug on lithium pharmacokinetics. Human Psychopharmacology, 1993, 8, 289-292.	1.5	4
202	Paradoxical Response to Tacrolimus Assessed by Interleukin-2 Gene Expression. Transplantation Proceedings, 2006, 38, 3327-3330.	0.6	4
203	Rapid analysis of tetracaine for a tape stripping pharmacokinetic study using shortâ€end capillary electrophoresis. Biomedical Chromatography, 2009, 23, 488-491.	1.7	4
204	The Relevance of Factor VIII (FVIII) Pharmacokinetics to TDM and Hemophilia A Treatment: Is B Domain–Deleted FVIII Equivalent to Full-Length FVIII?. Therapeutic Drug Monitoring, 2012, 34, 110-117.	2.0	4
205	Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. Journal of Medical Economics, 2012, 15, 253-260.	2.1	4
206	Association of genetic variation in telomereâ€related SNP and telomerase with ventricular arrhythmias in ischemic cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 261-266.	1.2	4
207	Safety and Pharmacokinetics of Levobupivacaine Following Fascia Iliaca Compartment Block in Elderly Patients. Drugs and Aging, 2019, 36, 541-548.	2.7	4
208	Influence of renal failure on disopyramide pharmacokinetics [proceedings]. British Journal of Clinical Pharmacology, 1979, 7, 427P-428P.	2.4	3
209	Oral theophylline in chronic heart failure. Postgraduate Medical Journal, 1982, 58, 216-221.	1.8	3
210	Subcutaneous infusion of bleomycin–a practical alternative to intravenous infusion Journal of Clinical Oncology, 1987, 5, 648-650.	1.6	3
211	Letter to the Editor. Human Toxicology, 1989, 8, 53-54.	0.9	3
212	Effects of amiodarone on the kinetics of antipyrine. American Journal of Cardiology, 1989, 63, 991-992.	1.6	3
213	Determination of medifoxamine in plasma and urine by high-performance liquid chromatography. Biomedical Applications, 1989, 496, 223-227.	1.7	3
214	Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans British Journal of Clinical Pharmacology, 1990, 30, 621-624.	2.4	3
215	Treatment of severe refractory atopic dermatitis with cyclosporin. Lancet, The, 1991, 338, 643-644.	13.7	3
216	The effect of age on the pharmacokinetics of pentisomide. Biopharmaceutics and Drug Disposition, 1991, 12, 627-631.	1.9	3

#	Article	IF	Citations
217	Does Bismuth Chelate Influence Lornoxicam Absorption?. Human and Experimental Toxicology, 1992, 11, 59-60.	2.2	3
218	The impact of cyclosporin formulation on clinical outcomes. Transplantation Proceedings, 2000, 32, 1552-1555.	0.6	3
219	Study of a combined percutaneous local anaesthetic and the TDSR system for venepuncture. Anaesthesia, 2006, 61, 123-126.	3.8	3
220	Tacrolimus Quality Assessment. Therapeutic Drug Monitoring, 1997, 19, 243.	2.0	3
221	Analysis of illicit drugs in purchased and seized electronic cigarette liquids from the United Kingdom 2014–2021. Drug Testing and Analysis, 2023, 15, 1058-1066.	2.6	3
222	Pharmacodynamic studies of verapamil after oral and i.v. administration in man [proceedings]. British Journal of Clinical Pharmacology, 1979, 8, 397P-398P.	2.4	2
223	Comparison of flupirtine and indomethacin on frusemide-induced diuresis. Postgraduate Medical Journal, 1987, 63, 959-961.	1.8	2
224	The interaction between chronic oral slow-release theophylline and single-dose intravenous erythromycin. Xenobiotica, 1987, 17, 493-497.	1.1	2
225	Plasma flecainide concentrations following acute myocardial infarction. International Journal of Cardiology, 1987, 15, 341-346.	1.7	2
226	Tolerability and Kinetics of Intravenous Medifoxamine in Healthy Volunteers. International Clinical Psychopharmacology, 1990, 5, 97-102.	1.7	2
227	Measurement of medifoxamine metabolites in urine by high-performance liquid chromatography. Biomedical Applications, 1990, 528, 531-536.	1.7	2
228	Hepatic \hat{l}^2 -adrenoceptor adaptation during propranolol administration is impaired in ageing rats. European Journal of Pharmacology, 1991, 208, 323-330.	2.6	2
229	Effects of repeated oral doses of TAK-013, a new non-peptide gonadotropin-releasing hormone (GnRH) antagonist, in healthy pre-menopausal women. Fertility and Sterility, 2002, 78, S280-S281.	1.0	2
230	On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region. European Journal of Internal Medicine, 2018, 48, e40-e41.	2.2	2
231	Quantification of mycophenolic acid in human plasma by liquid chromatography with timeâ€ofâ€flight mass spectrometry for therapeutic drug monitoring. Biomedical Chromatography, 2021, 35, e5011.	1.7	2
232	Fraud in medical science. Lancet, The, 1995, 346, 378.	13.7	1
233	Re: Drugs, driving and sobriety tests. Journal of Clinical Forensic and Legal Medicine, 2003, 10, 126-127.	0.8	1
234	Monitoring immunosuppressive drugs. Handbook of Analytical Separations, 2004, , 273-296.	0.8	1

#	Article	IF	CITATIONS
235	Measurement Of Tacrolimus. Does The Choice Of Anticoagulant Matter?. Therapeutic Drug Monitoring, 2005, 27, 222.	2.0	1
236	Cytosine arabinoside: pharmacokinetics following different routes of administration. Biochemical Society Transactions, 1982, 10, 512-513.	3.4	0
237	The disposition of inhaled lysine theophylline in volunteers. European Journal of Clinical Pharmacology, 1984, 26, 635-637.	1.9	0
238	CYCLOSPORIN RADIOIMMUNOASSAY AND CARDIAC TRANSPLANTATION. Lancet, The, 1988, 332, 459.	13.7	0
239	Determination of Oxidation Phenotype by Measurement of Propafenone Urinary Metabolic Ratios. Human and Experimental Toxicology, 1993, 12, 161-163.	2.2	0
240	The TMC study. Lancet, The, 2003, 361, 346-347.	13.7	0
241	THE EFFECTS OF HALOPERIDOL AND ARIPIPRAZOLE ON RESTING STATE BRAIN PERFUSION IN HEALTHY VOLUNTEERS. Schizophrenia Research, 2010, 117, 238-239.	2.0	0
242	Generic and therapeutic substitution: a response to our critic. International Journal of Clinical Pharmacy, 2011, 33, 881-881.	2.1	0
243	Integrating narrow therapeutic index drug formulations in transplantation. European Journal of Hospital Pharmacy, 2012, 19, 318-319.	1.1	0
244	The Smell of Death: An Unusual Case of Poisoning With the Organophosphorus Pesticide Chlorfenvinphos. Therapeutic Drug Monitoring, 2019, 41, 250-252.	2.0	0
245	IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS. Neuro-Oncology, 2021, 23, i27-i27.	1.2	0